Taysha Gene Therapies, Inc. (TSHA) stock
TSHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.00−0.06 (-1.48%)
Close on Nov 17, 2026Market cap $1.30BP/E –Yield –
Taysha Gene Therapies total assets
Total assets on the balance sheet at the end of each period.
Taysha Gene Therapies's total assets was $470.43M at Jun 30, 2026. For fiscal 2025 it was $343.32M, up 114.1% from the year before. The highest annual figure on record is $343.32M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $343.32M | +114.1% |
| FY2024 | Dec 31, 2024 | $160.36M | -7.2% |
| FY2023 | Dec 31, 2023 | $172.73M | +36.8% |
| FY2022 | Dec 31, 2022 | $126.28M | -41.0% |
| FY2021 | Dec 31, 2021 | $213.96M | -17.4% |
| FY2020 | Dec 31, 2020 | $258.88M | +1725773.3% |
| FY2019 | Dec 31, 2019 | $15.00K | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $470.43M | +41.1% |
| Q1 FY2026 | Mar 31, 2026 | $300.35M | +117.1% |
| Q4 FY2025 | Dec 31, 2025 | $343.32M | +114.1% |
| Q3 FY2025 | Sep 30, 2025 | $316.55M | +75.7% |
| Q2 FY2025 | Jun 30, 2025 | $333.33M | +66.3% |
| Q1 FY2025 | Mar 31, 2025 | $138.36M | -9.6% |
| Q4 FY2024 | Dec 31, 2024 | $160.36M | -7.2% |
| Q3 FY2024 | Sep 30, 2024 | $180.22M | -7.9% |
| Q2 FY2024 | Jun 30, 2024 | $200.39M | +145.8% |
| Q1 FY2024 | Mar 31, 2024 | $153.00M | +50.6% |
| Q4 FY2023 | Dec 31, 2023 | $172.73M | +36.8% |
| Q3 FY2023 | Sep 30, 2023 | $195.77M | +75.6% |
| Q2 FY2023 | Jun 30, 2023 | $81.54M | -42.7% |
| Q1 FY2023 | Mar 31, 2023 | $101.60M | -38.8% |
| Q4 FY2022 | Dec 31, 2022 | $126.28M | -41.0% |
| Q3 FY2022 | Sep 30, 2022 | $111.47M | -53.8% |
| Q2 FY2022 | Jun 30, 2022 | $142.33M | -41.2% |
| Q1 FY2022 | Mar 31, 2022 | $165.98M | -31.6% |
| Q4 FY2021 | Dec 31, 2021 | $213.96M | -17.4% |
| Q3 FY2021 | Sep 30, 2021 | $241.04M | -13.7% |
| Q2 FY2021 | Jun 30, 2021 | $241.86M | +1612300.0% |
| Q1 FY2021 | Mar 31, 2021 | $242.83M | – |
| Q4 FY2020 | Dec 31, 2020 | $258.88M | – |
| Q3 FY2020 | Sep 30, 2020 | $279.27M | – |
| Q4 FY2019 | Dec 31, 2019 | $15.00K | – |
See a number that looks wrong?